FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082439374> ?p ?o ?g. }

• W2082439374 endingPage "1273" @default.
• W2082439374 startingPage "1268" @default.
• W2082439374 abstract "The Adjuvant Chemotherapy Trial of TS-1 for Colon Cancer (ACTS-CC) is a phase III trial designed to validate the non-inferiority of S-1 to UFT/leucovorin (LV) as postoperative adjuvant chemotherapy for stage III colon cancer. We report the results of a planned safety analysis.Patients aged 20-80 years with curatively resected stage III colon cancer were randomly assigned to receive UFT/LV (UFT, 300 mg m(-2) per day as tegafur; LV, 75 mg per day on days 1-28, every 35 days, 5 courses) or S-1 (80, 100, or 120 mg per day on days 1-28, every 42 days, 4 courses). Treatment status and safety were evaluated.Of 1535 enrolled patients, a total of 1504 (756 allocated to S-1 and 748 to UFT/LV) were analysed. The completion rate of protocol treatment was 77% in the S-1 group and 73% in the UFT/LV group. The overall incidence of adverse events (AEs) were 80% in S-1 and 74% in UFT/LV. Stomatitis, anorexia, hyperpigmentation, and haematological toxicities were common in S-1, whereas increased alanine aminotransferase and aspartate aminotransferase were common in UFT/LV. The incidences of grade 3 AEs were 16% and 14%, respectively.Although AE profiles differed between the groups, feasibility of the protocol treatment was good. Both S-1 and UFT/LV could be safely used as adjuvant chemotherapy." @default.
• W2082439374 created "2016-06-24" @default.
• W2082439374 creator A5004055855 @default.
• W2082439374 creator A5005158019 @default.
• W2082439374 creator A5006987352 @default.
• W2082439374 creator A5008725648 @default.
• W2082439374 creator A5009546381 @default.
• W2082439374 creator A5010090426 @default.
• W2082439374 creator A5018454407 @default.
• W2082439374 creator A5025399736 @default.
• W2082439374 creator A5027118202 @default.
• W2082439374 creator A5027839397 @default.
• W2082439374 creator A5027999029 @default.
• W2082439374 creator A5033008284 @default.
• W2082439374 creator A5039563810 @default.
• W2082439374 creator A5040824519 @default.
• W2082439374 creator A5045989205 @default.
• W2082439374 creator A5046397472 @default.
• W2082439374 creator A5048058848 @default.
• W2082439374 creator A5054353327 @default.
• W2082439374 creator A5070887762 @default.
• W2082439374 creator A5087398756 @default.
• W2082439374 date "2012-03-01" @default.
• W2082439374 modified "2023-10-14" @default.
• W2082439374 title "Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial" @default.
• W2082439374 cites W1499419719 @default.
• W2082439374 cites W2013269714 @default.
• W2082439374 cites W2040872961 @default.
• W2082439374 cites W2077902459 @default.
• W2082439374 cites W2107943787 @default.
• W2082439374 cites W2121313610 @default.
• W2082439374 cites W2124381835 @default.
• W2082439374 cites W2137991416 @default.
• W2082439374 cites W2146161922 @default.
• W2082439374 cites W2153198430 @default.
• W2082439374 cites W2155639923 @default.
• W2082439374 cites W2168600267 @default.
• W2082439374 cites W2171232394 @default.
• W2082439374 doi "https://doi.org/10.1038/bjc.2012.86" @default.
• W2082439374 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3314794" @default.
• W2082439374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22415232" @default.
• W2082439374 hasPublicationYear "2012" @default.
• W2082439374 type Work @default.
• W2082439374 sameAs 2082439374 @default.
• W2082439374 citedByCount "34" @default.
• W2082439374 countsByYear W20824393742012 @default.
• W2082439374 countsByYear W20824393742013 @default.
• W2082439374 countsByYear W20824393742014 @default.
• W2082439374 countsByYear W20824393742015 @default.
• W2082439374 countsByYear W20824393742016 @default.
• W2082439374 countsByYear W20824393742017 @default.
• W2082439374 countsByYear W20824393742018 @default.
• W2082439374 countsByYear W20824393742020 @default.
• W2082439374 countsByYear W20824393742021 @default.
• W2082439374 countsByYear W20824393742022 @default.
• W2082439374 countsByYear W20824393742023 @default.
• W2082439374 crossrefType "journal-article" @default.
• W2082439374 hasAuthorship W2082439374A5004055855 @default.
• W2082439374 hasAuthorship W2082439374A5005158019 @default.
• W2082439374 hasAuthorship W2082439374A5006987352 @default.
• W2082439374 hasAuthorship W2082439374A5008725648 @default.
• W2082439374 hasAuthorship W2082439374A5009546381 @default.
• W2082439374 hasAuthorship W2082439374A5010090426 @default.
• W2082439374 hasAuthorship W2082439374A5018454407 @default.
• W2082439374 hasAuthorship W2082439374A5025399736 @default.
• W2082439374 hasAuthorship W2082439374A5027118202 @default.
• W2082439374 hasAuthorship W2082439374A5027839397 @default.
• W2082439374 hasAuthorship W2082439374A5027999029 @default.
• W2082439374 hasAuthorship W2082439374A5033008284 @default.
• W2082439374 hasAuthorship W2082439374A5039563810 @default.
• W2082439374 hasAuthorship W2082439374A5040824519 @default.
• W2082439374 hasAuthorship W2082439374A5045989205 @default.
• W2082439374 hasAuthorship W2082439374A5046397472 @default.
• W2082439374 hasAuthorship W2082439374A5048058848 @default.
• W2082439374 hasAuthorship W2082439374A5054353327 @default.
• W2082439374 hasAuthorship W2082439374A5070887762 @default.
• W2082439374 hasAuthorship W2082439374A5087398756 @default.
• W2082439374 hasBestOaLocation W20824393741 @default.
• W2082439374 hasConcept C120665830 @default.
• W2082439374 hasConcept C121332964 @default.
• W2082439374 hasConcept C121608353 @default.
• W2082439374 hasConcept C126322002 @default.
• W2082439374 hasConcept C141071460 @default.
• W2082439374 hasConcept C146357865 @default.
• W2082439374 hasConcept C151730666 @default.
• W2082439374 hasConcept C197934379 @default.
• W2082439374 hasConcept C2776694085 @default.
• W2082439374 hasConcept C2777299880 @default.
• W2082439374 hasConcept C2777863537 @default.
• W2082439374 hasConcept C526805850 @default.
• W2082439374 hasConcept C61511704 @default.
• W2082439374 hasConcept C71924100 @default.
• W2082439374 hasConcept C86803240 @default.
• W2082439374 hasConcept C90924648 @default.
• W2082439374 hasConceptScore W2082439374C120665830 @default.
• W2082439374 hasConceptScore W2082439374C121332964 @default.
• W2082439374 hasConceptScore W2082439374C121608353 @default.
• W2082439374 hasConceptScore W2082439374C126322002 @default.

• next